Brief: Unicycive Issued Notice Of Acceptance To Initiate Phase 1 Study Of Uni-494

Unicycive Therapeutics

22/12/2022 13:38

Dec 22 (Reuters) - Unicycive Therapeutics Inc  UNCY.O :
    * UNICYCIVE ISSUED NOTICE OF ACCEPTANCE TO INITIATE PHASE 1
STUDY
OF UNI-494 FOLLOWING REVIEW OF CLINICAL TRIAL APPLICATION BY THE
MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY IN THE
UNITED KINGDOM
    * UNICYCIVE - PLAN TO FILE IND APPLICATION WITH U.S. FDA IN
2023
FOR PHASE 2 PROOF-OF-CONCEPT TRIAL IN ACUTE KIDNEY INJURY
PATIENTS WITH BACKGROUND OF CKD

Source text for Eikon:  ID:nGNX6sTSht 
Further company coverage:  UNCY.O 
 ((Reuters.Briefs@thomsonreuters.com;))